Pharmaceutical Companies are investing heavily into Indications Discovery. There is a tremendous commercial and medical value in Drug Repositioning, or Drug Repurposing, i.e., finding a new indication for an existing drug. This presents an excellent strategy to achieve optimal potential and maximize the value of a therapeutic drug.
One of the bigger challenges is to connect the dots between currently approved drugs and new applications. Some of the issues which need to be addressed are how to deal with the increasing amount of data available from the interaction of these drugs in humans, how to deal with IP issues, and how to translate new chemical and biological knowledge of these drugs into safe and effective novel therapeutics. There is also an increasing demand for faster and less expensive ways of identifying potential hits. With the cost of bringing a new drug to market in the U.S. sometimes exceeding $1 billion by some estimates, this is a growing area of interest.
Coverage Includes:
Data Analysis
Pre-Clinical Testing in Disease Models
Targeting Metabolic Pathways
Meeting Current Regulatory Standards
Technologies for Indication Discovery
Turning “Off Target Effects” of Current Drugs into Novel Targets
Screening in Disease Models
Computational Approaches
Drug Repositioning for Neglected Diseases
Successful Case Studies for Drug Repositioning
Stay on to attend
Encouraging Development of Therapeutics for Neglected Diseases
(March 12-13, 2012)
- Promising Therapeutic Targets and Strategies
- Case Studies of Successful Collaborations
- Drug Repositioning
- Screening for Novel Therapeutic Possibilities
|
- Targeting Leishmania
- Open-Access Resources
- Success and Progress in NDs, Including Malaria and TB
|
Special discount is available to attend both events: Register today
|